Everyone wants to see children suffering from cancer get the best treatment possible. So why is it that we’re not providing them with such care?
Why is it that 80% of childhood cancer survivors develop chronic health issues from treatment?
And why is that only 5% of cancer drugs have been approved for first time use in children?
The Leukemia & Lymphoma Society, recognizing that children with blood cancers need to be treated differently – recognizing that a one-size treatment doesn’t fit all — is working to change that.
That’s why the Leukemia & Lymphoma Society launched The Dare to Dream Project, a bold and urgent $175 million capital campaign to transform their treatment and care. (Give here)
This groundbreaking global collaborative is an effort to accelerate pediatric, adolescent, and young adult blood cancer research and transform the treatment and care for pediatric patients.
Dare To Dream prioritizes and fuels the cutting-edge pediatric research, including the first-ever pediatric acute leukemia Master Clinical Trial, called LLS PedAL, advocacy, and free resources and support services necessary to save and improve even more young blood cancer patients’ and survivors’ lives.
Jana Boyer, the executive director of LLS New Jersey, explains the effort this way.
“Too many children are surviving cancer, only to face a lifetime of health complications from the treatments that saved them,” she said. “We believe kids deserve better — and Dare to Dream Days is our call to action.”
The aim to help will last all year – but Friday marks the end of the group’s Dare To Dream Days, a week-long effort to raise funds and consciousness of the issue.
You can give here.
